Relevant baseline characteristics for describing patients with knee osteoarthritis: results from a Delphi survey

[1] Cheung PP(2010)What are the best markers for disease progression in osteoarthritis (OA)? Best Pract Res Clin Rheumatol 24 81-92

[2] Gossec L(2012)Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature BMC Med Res Methodol 12 111-403

[3] Dougados M(2010)Critical appraisal of the meta-analysis by Wandel et al.- methodological aspects (part 2) BMJ 12 111-101

[4] Gagnier JJ(2000)Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative Osteoarthritis Cartilage 8 395-399

[5] Moher D(2012)OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials Osteoarthritis Cartilage 20 93-1654

[6] Boon H(2004)OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited Osteoarthritis Cartilage 12 389-1125

[7] Beyene J(2003)Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria J Rheumatol 30 1648-1371

[8] Bombardier C(2011)Patient characteristics that predict progression of knee osteoarthritis: a systematic review of prognostic studies Arthritis Care Res 63 1115-undefined

[9] Helg AG(1994)Users’ guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group JAMA 272 1367-undefined

[10] Dougados M(undefined)undefined undefined undefined undefined-undefined

[1] Cheung PP(2010)What are the best markers for disease progression in osteoarthritis (OA)? Best Pract Res Clin Rheumatol 24 81-92

[2] Gossec L(2012)Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature BMC Med Res Methodol 12 111-403

[3] Dougados M(2010)Critical appraisal of the meta-analysis by Wandel et al.- methodological aspects (part 2) BMJ 12 111-101

[4] Gagnier JJ(2000)Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative Osteoarthritis Cartilage 8 395-399

[5] Moher D(2012)OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials Osteoarthritis Cartilage 20 93-1654

[6] Boon H(2004)OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited Osteoarthritis Cartilage 12 389-1125

[7] Beyene J(2003)Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria J Rheumatol 30 1648-1371

[8] Bombardier C(2011)Patient characteristics that predict progression of knee osteoarthritis: a systematic review of prognostic studies Arthritis Care Res 63 1115-undefined

[9] Helg AG(1994)Users’ guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group JAMA 272 1367-undefined

[10] Dougados M(undefined)undefined undefined undefined undefined-undefined